Therapeutic Targets Database

THE PROSTATE CANCER FOUNDATION ANNOUNCES THE 2023 YOUNG INVESTIGATOR AWARDS TOTALING MORE THAN $6 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Tuesday, October 24, 2023
Physician, Prostate, Therapeutic Targets Database, PCF, CRPC, Prostate cancer, Prostate Cancer Foundation, PSMA, Research, Neoplasm, Medical imaging

LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2023 Young Investigator Award recipients totaling $6.1 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2023 Young Investigator Award recipients totaling $6.1 million in funding for innovative prostate cancer research.
  • PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field.
  • Twenty-eight PCF Young Investigator Awards totaling $6.1 million were awarded to the promising next generation of cancer researchers.
  • Project Title: Breaking Barriers in Prostate Cancer: Novel Clinical Uses of PSMA Radioligand Therapy and Imaging with PSMA PET/CT
    Project Title: Non-Invasive Prediction of Tumor Phenotypes, Therapeutic Targets, and Treatment Response in CRPC Using ctDNA

Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023

Retrieved on: 
Friday, August 25, 2023
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, COYA, CMU, Therapy, Therapeutic Targets Database, Biomedicine, Biomedical engineering, Medical device

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, announced that Dr. Phil Campbell, Professor of Biomedical Engineering at CMU, will discuss novel proof of concept data in his presentation, “Rapid Functionalization of Treg Exosomes for Targeted Immunotherapy” at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023.
  • The meeting registration and agenda can be located here.

Cerevance Announces Presentation at the Alzheimer’s Association International Conference

Retrieved on: 
Monday, July 10, 2023
Central nervous system, Therapy, Brain, Therapeutic Targets Database, CNS, AAIC, Drug discovery, Conference, Pharmaceutical industry, Cerev Del

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.

Key Points: 
  • BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
  • Title: NETSseq Advances the Understanding of Neuronal Vulnerability in Alzheimer’s Disease Progression Thereby Facilitating the Identification of Novel, Cell Type Specific, Therapeutic Targets
    Overview: Using Cerevance’s proprietary NETSseq platform, highly reproducible molecular profiles from cell types from the human brain have been produced.
  • As a result, Cerevance is generating novel insights and targets for Alzheimer’s disease drug discovery.

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Retrieved on: 
Thursday, May 11, 2023
Epilepsy, KV7, Seizure, Neuron, Therapy, MES, Eurosport 1, HERG, G&A, Therapeutic Targets Database, CNS, Homeostasis, Research and development, Patient, Administration, Central nervous system disease, R, Research, SCI, Chronic pain, Psychiatry, IND, Conference, Vaccine, Pharmaceutical industry, Cryptocurrency

SEATTLE and CAMBRIDGE, United Kingdom, May 11, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • “We were excited to share our initial preclinical data from ETX-123, our lead candidate in the Kv7 program, during the first quarter,” said Andrew Levin, M.D., Ph.D., executive chairman of Eliem Therapeutics.
  • Further screens also confirmed an encouraging broad selectivity profile, including no GABAA, hERG or other off-target activities at anticonvulsant doses.
  • Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

Retrieved on: 
Tuesday, March 21, 2023
Central nervous system, Therapy, Eurosport 1, Drug discovery, Cerev Del, Mechanical philosophy, Therapeutic Targets Database, CNS, Calcium, GPR55, Microglia, SCI, Conference, Kinetics, Pharmaceutical industry

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.

Key Points: 
  • BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.
  • 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
    Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK
    Title: Identification of THIK-1 as a therapeutic target for neuroinflammatory diseases: Discovery and characterisation of a selective THIK-1 blocker
    Overview: The NETSseq platform can identify unexplored and druggable microglia targets, exemplified by THIK-1, as potential therapies for neurodegenerative diseases.
  • The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored.
  • Overview: Three proprietary small molecule activators of GPR55 display unique signalling profiles when measuring the initial velocity of calcium and β-arrestin pathway activation.

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Investor, ADOA, TANGO, Nasdaq, Eye, Tissue, Therapy, Stoke, ID, Therapeutic Targets Database, Disease, Asos, Haploinsufficiency, Central nervous system, Dravet syndrome, Pharmaceutical industry

To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761.

Key Points: 
  • To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761.
  • The webinar will be broadcast live on the Investors & News section of Stokes website at https://investor.stoketherapeutics.com/ , and can be accessed by following this Link .
  • An archive replay of the webinar will be available for at least 90 days following the event.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Retrieved on: 
Monday, September 12, 2022
Software, Biotechnology, General Health, Health, Data Management, Health Technology, Technology, Genetics, Therapy, Gene editing, Chemical engineering, CRISPR, CIO, Therapeutic Targets Database, Senior, Acquisition, Growth, Industry, Berkeley, CEO, MBA, Amgen, Cancer, Nanotechnology, Notre Dame Institute for Global Investing, 5, Biotechnology, University of Washington Department of Bioengineering, Hemoglobinopathy, Multimedia, University, Management, Medical device, Pharmaceutical industry, Spotlight

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220912005015/en/
    "We are delighted to welcome Arvind to Spotlights leadership team.
  • "Arvind has deep experience in biologics and will play a key role in helping Spotlight bring a new class of CRISPR ribonucleoprotein therapeutics to patients.
  • Established in 2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.

Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member

Retrieved on: 
Tuesday, July 12, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Oncology, SVP, Therapeutic Targets Database, Biotechnology, Multimedia, Breast cancer, Development, Johnson & Johnson, Rhône-Poulenc, Daiichi Sankyo, Gene editing, Science, Leadership, Therapy, CRISPR, Patient, CEO, Notre Dame Institute for Global Investing, AstraZeneca, Director, CIO, Hemoglobinopathy, Board, Industry, Drug development, Merck, Vaccine, Pharmaceutical industry, Spotlight, Sanofi

Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc.

Key Points: 
  • Spotlight Therapeutics, Inc. (Spotlight), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc.
  • View the full release here: https://www.businesswire.com/news/home/20220704005433/en/
    We are thrilled to welcome Antoine to Spotlights Board of Directors, said Mary Haak-Frendscho, Ph.D., President and Chief Executive Officer of Spotlight.
  • Antoines deep insights and vast global pharma experience will help propel Spotlight to becoming a clinical stage company, said Craig Gordon, M.D., Spotlight board member, Founder, CEO, and CIO of GordonMD Global Investments.
  • Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies.

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Eye, Conference, Asos, Central nervous system, Haploinsufficiency, Therapeutic Targets Database, Webcast, Dravet syndrome, Disease, TANGO, Investor, Stoke, Nasdaq, Therapy, ADOA, Twitter, Tissue, Vaccine

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
  • Using Stokes proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
  • Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 5, 2022
Biotechnology, Genetics, Optical, Health, Therapy, Investor, Central nervous system, Conference, Webcast, TANGO, Dravet syndrome, Tissue, Twitter, Haploinsufficiency, Stoke, Nasdaq, Eye, ADOA, Asos, Therapeutic Targets Database, Disease, Vaccine

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
  • Using Stokes proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
  • Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.